Journal of Clinical Oncology, Vol 22, No 10 (May 15), 2004: pp. 1878-1885
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.12.002
RRM1 and PTEN As Prognostic Parameters for Overall and Disease-Free Survival in Patients With NonSmall-Cell Lung Cancer
Gerold Bepler,
Swati Sharma,
Alan Cantor,
Ashish Gautam,
Eric Haura,
George Simon,
Anupama Sharma,
Eric Sommers,
Lary Robinson
From the Thoracic Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Address reprint requests to Gerold Bepler, MD, PhD, Moffitt Cancer Center and Research Institute, Thoracic Oncology Program, MRC-4 West, 12902 Magnolia Dr, Tampa, FL 33612-9497; e-mail: beplerg{at}moffitt.usf.edu
PURPOSE: RRM1 has important functions in the determination of the malignant phenotype. It controls cell proliferation through deoxynucleotide production and metastatic propensity through PTEN induction. It is located in a region of loss of heterozygosity in nonsmall-cell lung cancer (NSCLC), which is a predictor of poor survival. We hypothesized that RRM1 expression would be a significant predictor of outcome in NSCLC.
PATIENTS AND METHODS: A retrospective data set of 49 patients and a prospective data set of 77 patients with resectable NSCLC were studied. RNA was extracted from tumor and normal lung tissue, and expression of the genes RRM1, PTEN, and RRM2 was determined by real-time quantitative polymerase chain reaction.
RESULTS: RRM1 expression was significantly correlated with PTEN and RRM2 expression in tumor tissue. RRM1 and PTEN expression in tumor tissue was highly predictive of overall (P = .011 and .018, respectively) and disease-free survival (P = .002 and .026, respectively). Patients with high levels of expression lived longer and had disease recurrence later than patients with low levels of RRM1 and PTEN. In a multivariate analysis, high RRM1 expression was predictive of long survival independent of tumor stage, performance status, and weight loss.
CONCLUSION: RRM1 is a biologically and clinically important determinant of malignant behavior in NSCLC. Knowing the level of expression of this gene adds significant information to management decisions independent of the currently used outcome predictors of tumor stage, performance status, and weight loss. Future clinical trials should stratify patients based on expression of this gene to avoid unwanted biases.
Supported in part by grant No. R01-CA102726 from the National Cancer Institute, Bethesda, MD.
Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. Plummer, C. Jones, M. Middleton, R. Wilson, J. Evans, A. Olsen, N. Curtin, A. Boddy, P. McHugh, D. Newell, et al.
Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
Clin. Cancer Res.,
December 1, 2008;
14(23):
7917 - 7923.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Simon, A. Sharma, X. Li, T. Hazelton, F. Walsh, C. Williams, A. Chiappori, E. Haura, T. Tanvetyanon, S. Antonia, et al.
Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
July 1, 2007;
25(19):
2741 - 2746.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Zheng, T. Chen, X. Li, E. Haura, A. Sharma, and G. Bepler
DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer
N. Engl. J. Med.,
February 22, 2007;
356(8):
800 - 808.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Bepler, I. Kusmartseva, S. Sharma, A. Gautam, A. Cantor, A. Sharma, and G. Simon
RRM1 Modulated In Vitro and In Vivo Efficacy of Gemcitabine and Platinum in Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
October 10, 2006;
24(29):
4731 - 4737.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Gautam and G. Bepler
Suppression of Lung Tumor Formation by the Regulatory Subunit of Ribonucleotide Reductase.
Cancer Res.,
July 1, 2006;
66(13):
6497 - 6502.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Cappuzzo, L. Toschi, G. Tallini, G. L. Ceresoli, I. Domenichini, S. Bartolini, G. Finocchiaro, E. Magrini, G. Metro, A. Cancellieri, et al.
Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib
Ann. Onc.,
July 1, 2006;
17(7):
1120 - 1127.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. W. Liu, S. T. Chen, and H. P. Liu
Choice of endogenous control for gene expression in nonsmall cell lung cancer
Eur. Respir. J.,
December 1, 2005;
26(6):
1002 - 1008.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Han, J. D. Ritzenthaler, B. Wingerd, and J. Roman
Activation of Peroxisome Proliferator-activated Receptor {beta}/{delta} (PPAR{beta}/{delta}) Increases the Expression of Prostaglandin E2 Receptor Subtype EP4: THE ROLES OF PHOSPHATIDYLINOSITOL 3-KINASE AND CCAAT/ENHANCER-BINDING PROTEIN {beta}
J. Biol. Chem.,
September 30, 2005;
280(39):
33240 - 33249.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Wang and M. You
Five Loci, SLT1 to SLT5, Controlling the Susceptibility to Spontaneously Occurring Lung Cancer in Mice
Cancer Res.,
September 15, 2005;
65(18):
8158 - 8165.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Zheng, G. Bepler, A. Cantor, and E. B. Haura
Small Tumor Size and Limited Smoking History Predicts Activated Epidermal Growth Factor Receptor in Early-Stage Non-small Cell Lung Cancer
Chest,
July 1, 2005;
128(1):
308 - 316.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Ferraro, G. Bepler, S. Sharma, A. Cantor, and E. B. Haura
EGR1 Predicts PTEN and Survival in Patients With Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
March 20, 2005;
23(9):
1921 - 1926.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|